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Abstract
Background: The anti–interleukin-6 receptor-alpha antibody tocilizumab was approved for intravenous (IV)
injection in the treatment of patients with systemic juvenile idiopathic arthritis (sJIA) aged 2 to 17 years based on
results of a randomized controlled phase 3 trial. Tocilizumab treatment in systemic juvenile idiopathic arthritis (sJIA)
patients younger than 2 was investigated in this open-label phase 1 trial and compared with data from the
previous trial in patients aged 2 to 17 years.
Methods: Patients younger than 2 received open-label tocilizumab 12 mg/kg IV every 2 weeks (Q2W) during a 12-
week main evaluation period and an optional extension period. The primary end point was comparability of
pharmacokinetics during the main evaluation period to that of the previous trial (in patients aged 2–17 years), and
the secondary end point was safety; pharmacodynamics and efficacy end points were exploratory. Descriptive
comparisons for pharmacokinetics, pharmacodynamics, safety, and efficacy were made with sJIA patients aged 2 to
17 years weighing < 30 kg (n = 38) who received tocilizumab 12 mg/kg IV Q2W in the previous trial (control group).
Results: Eleven patients (mean age, 1.3 years) received tocilizumab during the main evaluation period. The primary end
point was met: tocilizumab exposures for patients younger than 2 were within the range of the control group (mean [±
SD] μg/mL concentration at the end-of-dosing interval [Cmin]: 39.8 [±14.3] vs 57.5 [±23.3]; maximum concentration [Cmax]
postdose: 288 [±40.4] vs 245 [±57.2]). At week 12, pharmacodynamic measures were similar between patients younger
than 2 and the control group; mean change from baseline in Juvenile Arthritis Disease Activity Score-71 was − 17.4 in
patients younger than 2 and − 28.8 in the control group; rash was reported by 14.3 and 13.5% of patients, respectively.
Safety was comparable except for the incidence of serious hypersensitivity reactions (27.3% in patients younger than 2 vs
2.6% in the control group).
Conclusions: Tocilizumab 12mg/kg IV Q2W provided pharmacokinetics, pharmacodynamics, and efficacy in sJIA patients
younger than 2 comparable to those in patients aged 2 to 17 years. Safety was comparable except for a higher incidence
of serious hypersensitivity events in patients younger than 2 years.
Classification: Juvenile idiopathic arthritis.
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Background
Systemic juvenile idiopathic arthritis (sJIA) has historic-
ally been the most severe and difficult to treat form of
childhood arthritis, and treatment options were limited
in the past [1, 2]. Approximately 5 to 15% of children
with chronic arthritis in North America and Europe
have sJIA, which is distinct from other categories of
juvenile idiopathic arthritis (JIA) and is characterized by
chronic arthritis with systemic manifestations and in-
creased inflammatory markers [2–5]. Greater under-
standing of the biology of sJIA has led to improvements
in outcomes for patients with sJIA resulting from the
development of cytokine-targeted therapies [4]. The in-
flammatory cytokine interleukin-6 (IL-6) plays a patho-
genic role in sJIA [1, 6, 7]. Tocilizumab (TCZ) is a
humanized anti-human IL-6 receptor-alpha (IL-6Rα)
monoclonal antibody that blocks IL-6 signaling [8, 9].
TCZ is indicated for the treatment of sJIA and polyarti-
cular JIA (in patients 2–17 years of age), rheumatoid
arthritis, giant cell arteritis [9, 10], and chimeric antigen
receptor T-cell–induced cytokine release syndrome [9].
In the phase 3 TENDER study, patients 2 to 17 years
of age with active sJIA and inadequate responses to non-
steroidal anti-inflammatory drugs (NSAIDs) and gluco-
corticoids were randomly assigned to receive either TCZ
or placebo intravenously (IV) every 2 weeks (Q2W)
double-blind for 12 weeks [1]. Patients who weighed less
than 30 kg received TCZ 12mg/kg, whereas patients
who weighed ≥30 kg received TCZ 8mg/kg. Because
body weight influences exposure to TCZ, the difference
in dosing regimens was necessary to provide comparable
TCZ exposures for patients across the full range of body
weights examined. Results demonstrated that inhibition
of IL-6 with TCZ was efficacious in patients with severe,
persistent, and unresponsive sJIA and that adverse
events (AEs) were consistent with the known safety pro-
file of TCZ. Results of the TENDER study formed the
basis for United States Food and Drug Administration
(FDA) and European Medicines Agency (EMA) approval
of IV TCZ in 2011 for the treatment of patients with
sJIA 2 years of age or older.
The current study was conducted to investigate TCZ
treatment in patients with sJIA younger than 2 years and
is the first trial to investigate a biologic therapy in
children of this age with sJIA. Pharmacokinetics, safety,
pharmacodynamics, and efficacy of TCZ were
investigated and compared with data from patients in
the TENDER trial who weighed < 30 kg and received the
same TCZ dosing regimen of 12 mg/kg IV Q2W.
Patients and methods
Trial design
This trial in patients with sJIA younger than 2 years
(ClinicalTrials.gov, NCT01455701) was an open-label,
single-arm study with a 12-week main evaluation period
and an optional extension period that lasted from week
12 until the patient reached 2 years of age or received
treatment for 1 year, whichever was longer. In the previ-
ous TENDER study in patients with sJIA aged 2 to 17,
patients received TCZ IV Q2W at a dose of 8 mg/kg if
they weighed ≥30 kg or 12 mg/kg if they weighed < 30 kg
[1]. Because it was highly likely that patients younger
than 2 years would weigh < 30 kg, a TCZ dose of 12 mg/
kg IV Q2W was selected for the current study.
After a screening period of up to 3 weeks, eligible pa-
tients received a maximum of 6 doses of TCZ 12mg/kg
IV Q2W from baseline to week 10 during the main
evaluation period. Final evaluations occurred at week 12.
After completing the main evaluation period, patients
could enter the optional extension period and continue
to receive TCZ 12mg/kg IV Q2W if it was medically
warranted. Patients who did not enter the optional ex-
tension period underwent safety follow-up 4 and 8 weeks
after their last TCZ infusion. Efficacy and safety results
of the main evaluation period and safety results after
completion of the optional extension period of this trial
are reported. Results from this trial were compared with
those of patients aged 2 to 17 years who weighed < 30 kg
and received TCZ 12mg/kg IV Q2W in the TENDER
trial (control group).
Patients
Eligible patients were younger than 2 years, received a
diagnosis of sJIA based on the International League of
Associations for Rheumatology classification criteria [3],
had symptoms for ≥1month before screening, and had
uncontrolled sJIA despite treatment with glucocorticoids
and NSAIDs. Patients had to have ≥2 active joints with
or without fever (defined as ≥38 °C) attributed to sJIA.
Patients could not have had macrophage activation syn-
drome (MAS) within 3 months before the screening visit
or previous exposure to TCZ, and they had to
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discontinue any biologic treatment with an appropriate
washout period. The study was conducted in accordance
with the principles of the Declaration of Helsinki and
Good Clinical Practice and was approved by the institu-
tional review boards and/or ethics committees of the
participating centers (Additional file 1: Appendix 1).
Written informed consent to participate in the study
was obtained from the patients’ parents or legal
guardians.
Assessments
The primary end point was characterization of pharma-
cokinetics during 12 weeks of TCZ treatment; compari-
son was made to week 12 results from patients in the
control group of the TENDER study to investigate
whether individual pharmacokinetic parameters in chil-
dren younger than 2 years fell within the range reported
for older children. The safety of TCZ in combination
with stable, ongoing sJIA therapy through 12 weeks was
a secondary end point. Pharmacodynamics and efficacy
of TCZ for the 12-week treatment period were explora-
tory end points; pharmacodynamic measures were sol-
uble IL-6R (sIL-6R) levels, C-reactive protein (CRP)
levels, and erythrocyte sedimentation rate (ESR); Juvenile
Arthritis Disease Activity Score-71 (JADAS-71) and
systemic features (fever and rash from study diaries)
were efficacy end points. Anti-TCZ antibody (ADA) and
corresponding TCZ and sIL-6R concentrations at the
same time points were measured in all patients to assess
immunogenicity. Blood samples for ADA measurement
were taken at baseline, week 12, end of study, time of
withdrawal because of anaphylaxis or serious or nonseri-
ous hypersensitivity, and ≥ 6 weeks after the last TCZ
dose for patients who withdrew because of anaphylaxis
or hypersensitivity reactions (hypersensitivity reactions
were classified as any AE reported within 24 h after
initiation of the TCZ infusion with a relationship of not
“unrelated” to TCZ).
Statistical analysis
Descriptive statistics were produced for this study (see
Additional file 1: Appendix 2 for sample size calculation).
Analyses were conducted on all patients who had ≥1
serum pharmacokinetic sample with valid TCZ concentra-
tion data. A 2-compartment pharmacokinetic model with
combined first-order and Michaelis-Menten elimination
that was previously developed for TCZ in pediatric pa-
tients with data from the TENDER trial was used to derive
individual post hoc pharmacokinetic parameters using the
“POSTHOC” option in nonlinear mixed-effects modeling
(NONMEM) software. Individual post hoc pharmacoki-
netic parameters were subsequently used to obtain indi-
vidual exposure values (maximum observed postinfusion
serum concentration [Cmax], concentration at the end of a
dosing interval [Cmin], and systemic exposure—defined as
area under the serum concentration–time profile during
the 2-week dosing interval [AUC2weeks]) at steady state by
simulation. Post hoc pharmacokinetic exposure parame-
ters were used to compute individual patient Cmin, Cmax,
and AUC2weeks at week 12. Comparisons were performed
for observed TCZ trough concentrations (Ctrough) and
modeled data. GraphPad Prism was used to generate
graphs for pharmacokinetic parameters. Efficacy (JADAS-
71) analysis was performed using SAS 9.2 for tables and
SAS 9.4 for graphs.
Safety was assessed for the entire study period in all
enrolled patients who received ≥1 dose of study medica-
tion regardless of whether they withdrew from the study,
and efficacy was assessed in all patients who received ≥1
dose of study medication and had ≥1 efficacy assessment.
Results
Patients
Eleven patients younger than 2 years were screened and
enrolled from 11 centers (5 in the United States, 1 in
Argentina, 5 in Europe); each center enrolled 1 patient.
All patients received ≥1 dose of TCZ 12mg/kg and were
included in pharmacokinetic, safety, and efficacy ana-
lyses. Four patients withdrew from the main evaluation
period because of AEs (3 because of clinically confirmed
serious AEs of hypersensitivity and 1 because of an AE
of thrombocytopenia). Seven patients completed the
study to week 12 and entered the optional extension
period, whereupon they all received ≥1 dose of 12 mg/kg
TCZ IV Q2W (Fig. 1). Two patients withdrew prema-
turely from TCZ treatment during the optional exten-
sion period, 1 because of an AE and 1 because of
withdrawal of consent. Baseline demographics and dis-
ease characteristics of patients younger than 2 years in
this study and for the control group were as expected
for the different age groups and disease durations
(Table 1), though more of the patients younger than 2
years were female.
Pharmacokinetics
There was a 3.3-fold increase in observed mean Ctrough
from week 2 through week 12 of the treatment period in
patients younger than 2 years, which was consistent with
that observed in the control group from the previous
study (3.1-fold increase over 12 weeks in patients in the
control group) (Fig. 2a). After TCZ administration, mean
[±SD] observed TCZ Ctrough increased over time and
plateaued between weeks 10 (68.4 [±29.2] μg/mL) and
12 (69.2 [±42.0] μg/mL). The observed mean [SD]
Ctrough achieved at 12 weeks in patients younger than 2
years was comparable to that achieved in the control
group (70.6 [±30.6] μg/mL; n = 30). Similarly, model-pre-
dicted steady state mean (median [range]) TCZ
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Screened and
enrolled
N = 11
Treated with TCZ
12 mg/kg Q2W
N = 11 
Withdrew, n = 4
AEs: n = 4
• Hypersensitivity, day 15
• Hypersensitivity, day 15
• Urticaria, day 15
• Thrombocytopenia, day 15
Completed 12-week
MEP
n = 7
Continued to OEP
n = 7
Completed OEP to
week 56a
n = 1 
Withdrew, n = 2
AE: n = 1
• Increased transaminase 
levels, day 112
Patient decision: n = 1
Completed OEP to
week 20a
n = 1
Completed OEP to
week 48a
n = 1
Completed OEP to
week 50a
n = 2 
Fig. 1 Patients younger than 2 years of age: patient disposition. aTwo patients completed the OEP upon reaching age 2, 1 at week 20 and 1 at
week 56; 3 patients completed the OEP (last dose), 2 at week 50 and 1 at week 48. AE: adverse event; MEP: main evaluation period; OEP: optional
extension period; Q2W: every 2 weeks; TCZ: tocilizumab
Table 1 Baseline demographics and disease characteristics
Patients < 2 years of age
< 30 kg (NP25737) n = 11
Patients 2–17 years of age
(TENDER)a < 30 kg n = 38
Age, years 1.3 (0.33) 6.6 (3.3)
Min, max 0.83, 1.83 2, 16
Females, n (%) 7 (63.6) 18 (47)
Weight, kg 9.97 (1.38) 20.07 (5.93)
Disease duration, years 0.319 (0.17) 4.03 (3.160)
JADAS-71, median (min, max) 20.50b (9.0, 37.6) 32.70 (12.6, 96.1)
No. of active joints, median (min, max) 4.0 (2, 19) 13.5 (3, 71)
No. of joints with LOM, median (min, max) 3.0 (0, 15) 14.5 (0, 67)
Physician global VAS score, median (min, max) 62.0 (30, 98) 71.0 (28, 100)
ESR, mm/h 59.4b (27.5) 64.1 (29.76)
CRP level, mg/L, median (min to max) 33.3 (18.0 to 1190.0) 123.2 (5.36 to 1704.9)
Fever, n (%) 5 (45.5) 20 (53.0)c
Rash, n (%) 8 (72.7) 13 (34.0)
No. of patients exposed to previous biologics, n (%) 2 (18.2)d 28 (73.7)
Previous MTX use, n (%) 2 (18.2) 31 (81.6)
Previous glucocorticoid use, n (%) 8 (72.7) 36 (94.7)
All values are mean (SD) unless otherwise noted
CRP C-reactive protein, ESR erythrocyte sedimentation rate, IV intravenous, JADAS-71 Juvenile Arthritis Disease Activity Score in 71 joints, LOM limitation of
movement, MTX methotrexate, Q2W every 2 weeks, SD standard deviation, TCZ tocilizumab, VAS visual analog scale
aPatients weighing < 30 kg, TCZ 12mg/kg IV Q2W
bEfficacy-evaluable patients, n = 10
cFever present for the past 7 days
dTwo patients had received anakinra before study entry
Concomitant use
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exposures observed in patients younger than 2 years
were within the range of exposures in the older children:
Cmin, 39.8 (34.3 [19.2 to 61.7]) μg/mL vs 57.5 (54.3
[10.9 to 117]) μg/mL; Cmax, 288 (285 [195 to 347])
μg/mL vs 245 (244 [109 to 382])] μg/mL; AUC2weeks,
947 (896 [563 to 1273]) μg/mL·day vs 1341 (1279
[558 to 2412]) μg/mL·day) (Fig. 2b).
Pharmacodynamics
After the administration of TCZ in patients younger
than 2 years, mean [±SD] observed serum sIL-6R levels
increased, consistent with increasing TCZ concentra-
tions, and reached steady state at week 8 (Fig. 3a,
Additional file 2: Fig. S1). Levels of sIL-6R in patients
younger than 2 years (927 [±148] ng/mL) were generally
comparable to those of patients in the control group
(770 [204] ng/mL) (Additional file 2: Fig. S1). Outlier
values for serum sIL-6R concentrations at week 12
were observed in 2 of 11 patients younger than 2
years (2590 ng/mL and 2720 ng/mL).
At baseline, mean CRP and ESR (Fig. 3b, c) values
were 251 mg/L and 59.4 mm/h, respectively, and de-
creased rapidly after the first dose of TCZ. By week 12,
mean CRP and ESR values were within the normal range
(Fig. 3b, c). Overall, week 12 sIL-6R, CRP, and ESR
values were comparable to those for the control group.
Efficacy
JADAS-71 and component values improved during the
main evaluation period in patients younger than 2 years
(Additional file 3: Fig. S2). The median JADAS-71 was
20.5 at baseline, decreased to near minimal disease activ-
ity (< 3.80) by day 57, and was at minimal disease activity
(< 3.80) by day 85 (week 12). The percentage of patients
with fever or rash decreased over the course of the study
from baseline to week 12 (Table 2). The decrease in
fever and rash was rapid, with fever resolving in 70%
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Fig. 2 a Mean observed serum TCZ concentration–time profile in patients younger than 2 years of age and in patients 2 to 17 years of age and
model-predicted steady state pharmacokinetic parameters in patients younger than 2 years and in patients 2 to 17 years of age for (b) Cmin, (c)
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(7/10) of patients and rash resolving in 50% (5/10) of
patients as early as day 8, after the first dose. The
reduction in disease activity (median [minimum, max-
imum]) in patients younger than 2 years from baseline
to week 12 (20.5 [9.0, 37.6] to 2.90 [0.3, 16.1]) was
comparable to that observed for the control group at
week 12 (32.7 [12.6, 96.1] to 6.15 [0.5, 20.8]) (Table 2).
Reductions in individual JADAS-71 components and
number of joints with limitation of movement were
also similar between patients younger than 2 years
and the control group (Table 2). Oral corticosteroid
dose was stable, then decreased by approximately 40%
from week 8 to week 12, for patients younger than 2
years (Additional file 4: Fig. S3), consistent with the
decrease in corticosteroid dose observed in the con-
trol group [1].
Safety
Main evaluation period
During the main evaluation period of the study,
most patients younger than 2 years had ≥1 AE (10/
11 patients; 90.9%). The nature of AEs was compar-
able between the age groups in both studies
(Table 3); however, a higher percentage of patients
younger than 2 years experienced AEs that led to
withdrawal (3 because of clinically confirmed serious
AEs of hypersensitivity and 1 because of a nonseri-
ous AE of thrombocytopenia). During the main
evaluation period, 3 of 11 (27.3%) patients experi-
enced SAEs; 2 patients reported 1 SAE each (hyper-
sensitivity and urticaria), both of which were
considered by the investigator to be related to TCZ
treatment and led to study discontinuation. One
patient reported 3 SAEs (hypersensitivity, hand-foot-
and-mouth disease, and JIA flare); only hypersensi-
tivity was considered by the investigator to be
related to TCZ treatment and led to withdrawal; the
other 2 SAEs occurred during the safety follow-up
period. There were no other serious infections dur-
ing the main evaluation period.
There were 4 clinically confirmed hypersensitivity
events in the main evaluation period (Table 3). One
patient experienced mild, nonserious urticaria after
the day 1 TCZ infusion, and 3 patients experienced
serious hypersensitivity reactions during or immedi-
ately after the day 15 TCZ infusion (2 hypersensitiv-
ity, 1 urticaria) that led to withdrawal. The 2 serious
events of hypersensitivity involved multiple signs and
symptoms and were associated with confounding
factors: in 1 patient, an administration error of faster
infusion rate occurred; in the other, a concomitant
diagnosis of subclinical MAS was made (Additional
file 1: Appendix 3). All 4 confirmed hypersensitivity
events resolved without sequelae after treatment.
Three patients who tested negative for anti-TCZ
antibodies at baseline tested positive for anti-TCZ
antibodies after TCZ treatment during the main
evaluation period. These patients were at the lower
end of the predose TCZ exposure range at day 15
(Additional file 5: Fig. S4) and were withdrawn from
the study because of AEs (2 hypersensitivity, 1
thrombocytopenia) on day 15 after their second TCZ
infusion. These patients received only 2 doses; there-
fore, efficacy could not be adequately assessed.
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Total observation period (main evaluation period and
optional extension period)
Throughout the course of the study (main evaluation
period and optional extension period) in patients youn-
ger than 2 years, most (90.9%; 10/11) were reported to
have ≥1 AE (Table 3). SAEs were reported by 5 of 11
patients (45.5%). Two occurred during the optional
extension period: 1 patient had increased transaminase
levels, considered by the investigator to be related to
treatment with both TCZ and concomitant methotrex-
ate, and was withdrawn from the optional extension
period; another patient experienced MAS (reported as
hemophagocytic histiocytosis), which was considered
unrelated to TCZ treatment and resolved after tempor-
ary dose interruption and treatment with methylpredni-
sone. Neither of these patients had other clinical
symptoms of MAS. No serious infections were reported
during the optional extension period; hence, the total
number of serious infections during the total observation
period was the single event of hand-foot-and-mouth
disease reported in the safety follow-up after withdrawal
from the main evaluation period. No clinically confirmed
Table 2 Change from baseline to week 12 in JADAS-71
Patients < 2 years of age
< 30 kg n = 11
Patients 2–17 years of agea
< 30 kg n = 38
JADAS-71b
Baseline 20.5 (9.0 to 37.6), n = 10 32.7 (12.6 to 96.1), n = 38
Change from baseline to week 12 −13.9 (− 2.7 to − 10.1), n = 5c −25.8 (− 91.2 to 0.0), n = 38
No. of joints with LOM
Baseline 3.0 (0 to 15), n = 11 14.5 (0 to 67), n = 38
Change from baseline to week 12 −3.0 (− 9 to 0), n = 7 − 8.0 (− 6 to 28), n = 37
JADAS-71 componentb
Physician global VAS score, mm
Baseline 62.0 (30 to 98), n = 11 71.0 (28 to 100), n = 38
Change from baseline to week 12 −44.0 (− 69 to − 37), n = 7 − 50.0 (− 99 to − 9), n = 37
Parent global VAS score, mm
Baseline 55.0 (10 to 99), n = 11 65.5 (8 to 100), n = 38
Change from baseline to week 12 −28.0 (− 85 to − 21), n = 7 − 42.0 (− 100 to − 6), n = 37
No. of active joints
Baseline 4.0 (2 to 19), n = 11 13.5 (3 to 71), n = 38
Change from baseline to week 12 −7.0 (− 16 to − 2), n = 7 − 10.0 (− 68 to − 1), n = 37
Fever and rash
Presence of fever, n/N (%)
Baseline 9/11 (81.8) 26/38 (68.4)
Week 12 1/7 (14.3) 1/37 (2.7)
Presence of rash, n/N (%)
Baseline 8/11 (72.7) 13/38 (34.2)
Week 12 1/7 (14.3) 5/37 (13.5)
Acute-phase reactants
CRP level, mg/L
Baseline 33.3 (18.0 to 1190.0), n = 11 123.2 (5.36 to 1704.9), n = 38
Change from baseline to week 12 − 74.1 (1181.0 to − 13.0), n = 6 − 123.1 (−1704.6 to −5.23), n = 36
ESR, mm/h
Baseline 57.0 (10.0 to 100.0), n = 10 69.0 (8 to 130), n = 38
Change from baseline to week 12 − 59.0 (− 78.0 to − 6.0), n = 5 − 65.0 (− 126 to − 7), n = 37
All values are median (min to max) unless otherwise noted
CRP C-reactive protein, ESR erythrocyte sedimentation rate, IV intravenously, JADAS-71 Juvenile Arthritis Disease Activity Score in 71 joints, LOM limitation of
movement, Q2W every 2 weeks, TCZ tocilizumab, VAS visual analog scale
aPatients weighing < 30 kg and receiving 12 mg/kg TCZ IV Q2W includes patients who were receiving placebo at baseline and switched to TCZ after week 12
bEfficacy-evaluable patients
cPatients who did not withdraw
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hypersensitivity reactions were reported in the optional
extension period; therefore, during the total observation
period, 4 (36.4%) clinically confirmed events were
reported. During the entire study, AEs leading to dose
interruption occurred in 5 of 11 patients (1 in the main
evaluation period, 4 in the optional extension period)
(Table 3), primarily because of infections, neutropenia,
and elevated liver enzymes, all mild or moderate in
intensity. No deaths in patients younger than 2 years
occurred during this study.
Discussion
Until recent years, treatment of sJIA was challenged by
limited therapeutic options. However, the outcome for
patients with sJIA has substantially improved since the
development of cytokine antagonists. The phase 3 TEN-
DER study of TCZ in patients with sJIA resulted in FDA
and EMA approval of IV TCZ for the treatment of pa-
tients 2 years or older, but sJIA can be diagnosed in even
younger patients. Very young patients have been shown
to exhibit more severe inflammatory features and a risk
for worse outcomes [11]. To allow rational interpret-
ation of data from this study of a small population of
patients with a severe disease, the focus of the research
was to facilitate a comparison of key measures influen-
cing the well-characterized efficacy of TCZ. It was antic-
ipated that comparable results in pharmacokinetics
would likely translate to comparable outcomes in
pharmacodynamics, safety, and efficacy. Therefore, this
open-label study investigated the pharmacokinetics,
safety, pharmacodynamics, and efficacy of IV TCZ in
children with sJIA younger than 2 years. The most rele-
vant control group for comparison was the subgroup of
patients from the TENDER study whose body weight
was below the same cutoff (< 30 kg) and who received
the same dosing regimen (12 mg/kg TCZ IV Q2W). Al-
though body size has been identified as the key demo-
graphic factor influencing exposure to TCZ [12], it is
possible that ontogenic factors (such as age and matur-
ation-related factors) influence exposure to TCZ, as they
do with other monoclonal antibodies [13]. Data from in-
fants treated with monoclonal antibodies are limited; re-
sults from the current trial provide the first
pharmacokinetic exposure data for a biologic in patients
with sJIA in this age range. During the 12-week main
evaluation period of the study in patients with sJIA
younger than 2 years, the 12mg/kg TCZ IV Q2W regi-
men resulted in pharmacokinetic, pharmacodynamic,
and efficacy results that were consistent with week 12
results for the control group of older patients with sJIA
treated with the same regimen. Although no direct evi-
dence rules out differences in the etiology of the disease
between the age groups, the data generated in this study
indicate consistency in exposure and efficacy between
patients younger than 2 years and the population of
patients 2 years and older. All patients in the current
study achieved reductions in disease activity from week
12 to baseline—measured by number of patients with
fever and systemic inflammation, number of joints with
limitation of movement, and JADAS-71 scores—
Table 3 Safety
Adverse events Patients < 2 years of age < 30 kg n = 11 Patients 2–17 years of agea
< 30 kg n = 38
12-week MEP Entire study First 12 weeks
Patients with ≥1 AE
AE 10 (90.9) 10 (90.9) 33 (86.8)
SAE 3 (27.3) 5 (45.5) 2 (5.3)
AE with fatal outcome 0 0 0
AE leading to withdrawal 4 (36.4) 5 (45.5) 1 (2.6)
AE leading to dose interruption 1 (9.1) 5 (45.5) 4 (10.5)
Infection
AE 9 (81.8) 9 (81.8) 23 (60.5)
SAE 1 (9.1) 1 (9.1) 1 (2.6)
Hypersensitivity reactionsb
Clinically confirmed 4 (36.4) 4 (36.4) 1 (2.6)
Serious 3 (27.3) 3 (27.3) 1 (2.6)
Low neutrophil count (grade≥ 3) 1 (9.1) 3 (27.3) 3 (7.9)
Low platelet count (grade≥ 3) 1 (9.1) 0 0
All data are number (%) of patients with event
AE adverse event, IV intravenously, MEP main evaluation period, Q2W every 2 weeks, SAE serious adverse event, TCZ tocilizumab
aPatients weighing < 30 kg and receiving TCZ 12 mg/kg IV Q2W
bSee Additional file 1: Appendix 3 for full details of patients with hypersensitivity reactions
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comparable to those for older children in the control
group. Results observed for pharmacodynamic parame-
ters (sIL-6R, CRP, ESR) were comparable between
patients younger than 2 years and the control group of
older patients. Pharmacokinetic exposures obtained in
this study in patients younger than 2 years led to the
expected pharmacodynamic response in that sIL-6R
builds to a plateau after repeated dosing with TCZ as it
forms a complex with TCZ [14].
The safety profile for 12 mg/kg TCZ IV Q2W during
12 weeks of treatment in this study was similar between
patients younger than 2 years and the control group of
patients aged 2 to 17 years, except for a higher incidence
of serious hypersensitivity events in patients younger
than 2 years. All 3 serious hypersensitivity events oc-
curred during or immediately after the second TCZ
infusion (day 15). Two of the patients who had serious
hypersensitivity events developed ADAs, detected after
day 15. Another patient who was positive for ADA after
day 15 did not experience any clinically confirmed
hypersensitivity events. Therefore, in this small sample
of 11 patients, there does not appear to be a relationship
between ADA and hypersensitivity reactions, but such a
relationship cannot be definitively ruled out because of
the small sample size.
Safety results from the optional extension period of
this study in sJIA patients younger than 2 years were
generally consistent with those of the main evaluation
period, and no additional safety signals were identified
other than the higher incidence of serious hypersensitiv-
ity in the main evaluation period. During the course of
the study, most AEs were mild or moderate in intensity,
and the types of AEs observed were consistent with the
known safety profile of TCZ for sJIA. During the op-
tional extension period, TCZ treatment was well toler-
ated in patients younger than 2 years, and no additional
safety signals were noted. However, because of the small
sample size and the confounding clinical factors for 2 of
the 3 serious hypersensitivity events that occurred in the
main evaluation period (faster than normal TCZ infu-
sion rate and subclinical MAS [15]), no definitive con-
clusions can be made regarding the safety of TCZ IV for
patients with sJIA younger than 2 years. Other limita-
tions of the current study of TCZ in patients with sJIA
younger than 2 years include the lack of a placebo com-
parator and the lack of statistical comparisons.
Conclusion
In conclusion, the dosing regimen of 12 mg/kg IV TCZ
Q2W provided pharmacokinetics, pharmacodynamics,
and efficacy data in sJIA patients younger than 2 years
comparable to those in patients 2 years of age or older.
Safety was comparable except for a higher incidence of
serious hypersensitivity events in the younger patients.
Previous presentation The data in this manuscript
were presented at the following congresses:
 EULAR 2018 (European League Against
Rheumatism); June 13–16, 2018; Amsterdam,
Netherlands – Mallalieu NL et al. Ann Rheum Dis
2018;77(suppl). Abstract 102.
 2018 ACR/ARHP (American College of
Rheumatology); October 19–24, 2018; Chicago,
Illinois – Wimalasundera S et al. Arthritis
Rheumatol 2018;70(suppl 10). Abstract 1413.
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